Scientists have discovered three powerful new drug regimens that offer more effective treatment for tuberculosis—bringing ...

Launch of Hyde Park Discovery between UChicago, Deerfield Management to accelerate research into life-saving treatments ...

Scientists have discovered a potential new treatment for familial hypercholesterolemia, inspired by signs seen in the Mona ...

Manas AI secures funding led by General Catalyst to scale AI-driven drug discovery, tackling cancer and rare diseases.

Multi-Modal Models: A multi-modal discovery approach was implemented that engineered-in potency against the novel target and engineered-out a specific off-target interaction. The NCE library displayed ...

Research co-led by University of Toronto researchers and Insilico Medicine has demonstrated the potential of quantum ...

Manas AI, a full-stack, AI-driven company focused on discovering and advancing next generation medicines, launched today. By leveraging its ...

A new study from Oregon Health & Science University has uncovered how small molecules within bacteria interact with proteins, ...

Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront of AI-driven drug discovery, yesterday commented on the announcement of a $500 billion private-sector investment ...

Sydney researchers have found that Levofloxacin substantially reduces risk of drug-resistant tuberculosis. This discovery offers new hope against a disease that infects more than 400,000 people ...

AUSTIN - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a micro-cap biotech company with a market capitalization of $18.78 ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. By ...